Safety and efficacy of everolimus plus exemestane in postmenopausal women with treatment-refractory hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Analysis from EVEREXES Taiwan subset-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety and efficacy of everolimus plus exemestane in postmenopausal women with treatment-refractory hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Analysis from EVEREXES Taiwan subset

Published:2023 Issue:3 Volume:10 Page:94
ISSN:2311-3006
Container-title:Journal of Cancer Research and Practice
language:en
Short-container-title:J Cancer Res Pract

Author:

Huang Chiun-Sheng,Chang Yuan-Ching,Rau Kun-Ming,Chen Dar-Ren,Chao Tsu-Yi,Hou Ming-Feng

Publisher

Medknow

Subject

General Medicine

Reference32 articles.

1. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global cancer observatory. In: Cancer Tomorrow. Lyons, France: International Agency for Research on Cancer; 2020. Available from: https://gco.iarc.fr/tomorrow.[Last accessed on 2020 Jun 12].

2. Extending survival with chemotherapy in metastatic breast cancer;O'Shaughnessy;Oncologist,2005

3. Estrogen receptors and cell proliferation in breast cancer;Ciocca;Trends Endocrinol Metab,1997

4. Treatment of estrogen receptor-positive breast cancer;Lumachi;Curr Med Chem,2013

5. Mechanisms of endocrine resistance in breast cancer;Osborne;Annu Rev Med,2011

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP